Authors: John E. Buckholz, Barry R. Jones, Raymond F. Biondolillo, Robert M. Sturm, Philip E. Joyce, Danielle J. Strong, John R. Perkins, Jennifer M. Cox and Bradley L. AckermannDownload our scientific poster to learn about the measurement of the endogenous analytes adenosine 3′,5′-cyclic monophosphate (cAMP) and guanosine 3′,5′-cyclic monophosphate (cGMP) via a surrogate matrix approach. A method was developed that demonstrated excellent statistical results; however, during validation, dilution of unfortified control plasma with surrogate matrix showed a positive bias for cGMP but not cAMP. An increase in cGMP mean endogenous level was also observed. The cause of this positive bias was an occasional co-eluting interferent present in ~20% of samples. Addition of trifluoroacetic acid (TFA) to the mobile phase solutions allowed for baseline resolution of the interferent from cGMP.
Q2 Solutions is your partner of choice for any development program which requires identifying or measuring biomarkers. Through our experience and expertise we can help you understand how these biomarkers can deliver actionable medical insights for better health. Q2 Solutions has developed >150 new biomarker assay every year since 2015.